The Committee discusses Geron Corporation’s New Drug Application (NDA) 217779 for Imetelstat for injection for the proposed indication for treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes on March 14 at 9:03 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GERN:
- B. Riley sees closely contested vote after ‘hair-raising’ Geron briefing docs
- FDA says ‘not clear’ magnitude, durability of RBC-TI outweighs Geron drug risks
- Needham biotechnology analyst to hold an analyst/industry conference call
- FDA Oncologic Drugs Advisory Committee holds virtual meeting
- Geron price target lowered to $4.50 from $5 at Baird